With the acquisition of Seagen Inc. late last year, Pfizer Inc. has positioned itself as a leader in the field of antibody-drug conjugates (ADCs) for the treatment of cancer. The company offered investors a glimpse at some of the next-generation ADC technologies it is pursuing during an oncology innovation overview on 29 February.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?